Cancer Testis Antigen and Immunotherapy

Overview

Journal Immunotargets Ther

Publisher Dove Medical Press

Specialty Allergy & Immunology

Date 2016 Jul 30

PMID 27471684

Citations 29

Authors

Deepa Kolaseri Krishnadas

Fanqi Bai

Kenneth G Lucas

Affiliations

Soon will be listed here.

Abstract

The identification of cancer testis (CT) antigens has been an important advance in determining potential targets for cancer immunotherapy. Multiple previous studies have shown that CT antigen vaccines, using both peptides and dendritic cell vaccines, can elicit clinical and immunologic responses in several different tumors. This review details the expression of melanoma antigen family A, 1 (MAGE-A1), melanoma antigen family A, 3 (MAGE-A3), and New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in various malignancies, and presents our current understanding of CT antigen based immunotherapy.

Citing Articles

Preparation of Phage Display cDNA Libraries for Identifying Immunogenic Tumor Antigens: Challenges in Functional cDNA Presentation and Approaches to Overcoming Them.

Brisar N, Suster K, Cor A Viruses. 2025; 16(12.

PMID: 39772164 PMC: 11680138. DOI: 10.3390/v16121855.

The progress of tumor vaccines clinical trials in non-small cell lung cancer.

Wang X, Niu Y, Bian F Clin Transl Oncol. 2024; .

PMID: 39179939 DOI: 10.1007/s12094-024-03678-z.

Cancer/testis antigen expression and co-expression patterns in gastroesophageal adenocarcinoma.

Kalvapudi S, Pachimatla A, Seager R, Conroy J, Pabla S, Mukherjee S Med Oncol. 2024; 41(9):227.

PMID: 39143271 PMC: 11324668. DOI: 10.1007/s12032-024-02475-6.

Expression pattern analysis of the family genes in breast cancer patients and hypomethylation activation in the MCF-7 cells.

Almatrafi A, Alamery S, Almutairi M Heliyon. 2024; 10(14):e34506.

PMID: 39082035 PMC: 11284374. DOI: 10.1016/j.heliyon.2024.e34506.

Cancer/testis antigen expression and co-expression patterns in Gastroesophageal Adenocarcinoma.

Kalvapudi S, Pachimatla A, Seager R, Conroy J, Pabla S, Mukherjee S Res Sq. 2024; .

PMID: 38947068 PMC: 11213187. DOI: 10.21203/rs.3.rs-4499622/v1.

References

Choi B, Cai M, Bigner D, Mehta A, Kuan C, Sampson J . Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther. 2011; 11(7):843-53. DOI: 10.1517/14712598.2011.572874. View

Adair S, Hogan K . Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother. 2008; 58(4):589-601. PMC: 11029901. DOI: 10.1007/s00262-008-0582-6. View

Bender A, Karbach J, Neumann A, Jager D, Al-Batran S, Atmaca A . LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun. 2007; 7:16. PMC: 2935748. View

Zhang S, Zhou X, Yu H, Yu Y . Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer. 2010; 10:163. PMC: 2868811. DOI: 10.1186/1471-2407-10-163. View

Vanneman M, Dranoff G . Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012; 12(4):237-51. PMC: 3967236. DOI: 10.1038/nrc3237. View

Yee C, Thompson J, Byrd D, Riddell S, Roche P, Celis E . Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002; 99(25):16168-73. PMC: 138583. DOI: 10.1073/pnas.242600099. View

Pastorcic-Grgic M, Sarcevic B, Dosen D, Juretic A, Spagnoli G, Grgic M . Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer. Head Neck. 2009; 32(9):1178-84. DOI: 10.1002/hed.21314. View

Farsaci B, Higgins J, Hodge J . Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer. 2011; 130(8):1948-59. PMC: 3232304. DOI: 10.1002/ijc.26219. View

Weber J . Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007; 12(7):864-72. DOI: 10.1634/theoncologist.12-7-864. View

10.

Morgan R, Dudley M, Wunderlich J, Hughes M, Yang J, Sherry R . Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314(5796):126-9. PMC: 2267026. DOI: 10.1126/science.1129003. View

11.

Comito M, Sun Q, Lucas K . Immunotherapy for Epstein-Barr virus-associated tumors. Leuk Lymphoma. 2004; 45(10):1981-7. DOI: 10.1080/10428190410001700831. View

12.

Stagg J, Loi S, Divisekera U, Ngiow S, Duret H, Yagita H . Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011; 108(17):7142-7. PMC: 3084100. DOI: 10.1073/pnas.1016569108. View

13.

Bao L, Dunham K, Lucas K . MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother. 2011; 60(9):1299-307. PMC: 11029270. DOI: 10.1007/s00262-011-1037-z. View

14.

Luiten R, van der Bruggen P . A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. Tissue Antigens. 2000; 55(2):149-52. DOI: 10.1034/j.1399-0039.2000.550206.x. View

15.

Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S . Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res. 2008; 68(10):3931-40. DOI: 10.1158/0008-5472.CAN-07-5898. View

16.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

17.

Gulley J, Arlen P, Bastian A, Morin S, Marte J, Beetham P . Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005; 11(9):3353-62. DOI: 10.1158/1078-0432.CCR-04-2062. View

18.

Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G . Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res. 2005; 29(7):739-48. DOI: 10.1016/j.leukres.2004.11.022. View

19.

Kono K, Takahashi A, Sugai H, Fujii H, Choudhury A, Kiessling R . Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res. 2002; 8(11):3394-400. View

20.

Nicholaou T, Ebert L, Davis I, Robson N, Klein O, Maraskovsky E . Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol. 2006; 84(3):303-17. DOI: 10.1111/j.1440-1711.2006.01446.x. View